Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Freezes Inspections And Outside Meetings. Will Review Goal Dates Stay Put?

Executive Summary

Sponsors have been asked to switch to teleconferences with FDA staff as the agency prepares for more of its employees to work from home.

You may also be interested in...



Complete Response Letters In Lieu Of Inspections: What To Expect During COVID-19

Complete Response Letters In Lieu Of Inspections: What To Expect During COVID-19

If agency has concerns about facilities it cannot inspect, it will generally issue complete responses, Q&A guidance says.

How The US FDA Finds Pre-Approval Inspection Alternatives During COVID-19 Pandemic

Officials explain how remote record reviews, site transfers and other factors can green-light approvals of drugs and biologics.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID001014

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel